Cargando…

Fasiglifam (TAK-875), a G Protein-Coupled Receptor 40 (GPR40) Agonist, May Induce Hepatotoxicity through Reactive Oxygen Species Generation in a GPR40-Dependent Manner

Fasiglifam (TAK-875) a G-protein coupled receptor 40 (GPR40) agonist, significantly improves hyperglycemia without hypoglycemia and weight gain, the major side effects of conventional anti-diabetics. Unfortunately, during multi-center Phase 3 clinical trials, unexpected liver toxicity resulted in pr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kim, MinJeong, Gu, Gyo Jeong, Koh, Yun-Sook, Lee, Su-Hyun, Na, Yi Rang, Seok, Seung Hyeok, Lim, Kyung-Min
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Korean Society of Applied Pharmacology 2018
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6254646/ https://www.ncbi.nlm.nih.gov/pubmed/29429148 http://dx.doi.org/10.4062/biomolther.2017.225

Ejemplares similares

Fasiglifam (TAK‐875) has dual potentiating mechanisms via Gαq‐GPR40/FFAR1 signaling branches on glucose‐dependent insulin secretion
por: Sakuma, Kensuke, et al.
Publicado: (2016)

Pharmacometric Approaches to Guide Dose Selection of the Novel GPR40 Agonist TAK-875 in Subjects With Type 2 Diabetes Mellitus
por: Naik, H, et al.
Publicado: (2013)

Randomized, Double-Blind, Dose-Ranging Study of TAK-875, a Novel GPR40 Agonist, in Japanese Patients With Inadequately Controlled Type 2 Diabetes
por: Kaku, Kohei, et al.
Publicado: (2013)

Ginseng Gintonin Contains Ligands for GPR40 and GPR55
por: Cho, Yeon-Jin, et al.
Publicado: (2020)

Evaluation of the hepatotoxicity of the novel GPR40 (FFAR1) agonist CPL207280 in the rat and monkey
por: Bazydlo-Guzenda, Katarzyna, et al.
Publicado: (2021)

Identification of Crocetin as a Dual Agonist of GPR40 and GPR120 Responsible for the Antidiabetic Effect of Saffron
por: Zhao, Xiaodi, et al.
Publicado: (2023)

A Novel Antidiabetic Drug, Fasiglifam/TAK-875, Acts as an Ago-Allosteric Modulator of FFAR1
por: Yabuki, Chiori, et al.
Publicado: (2013)

GPR40: Good Cop, Bad Cop?
por: Alquier, Thierry, et al.
Publicado: (2009)

GPR40 Modulators: New Kid on the Block
por: Basu, Ananda, et al.
Publicado: (2013)

Predicting GPR40 Agonists with A Deep Learning‐Based Ensemble Model
por: Yang, Jiamin, et al.
Publicado: (2023)

Efficacy and safety of fasiglifam (TAK-875), a G protein-coupled receptor 40 agonist, in Japanese patients with type 2 diabetes inadequately controlled by diet and exercise: a randomized, double-blind, placebo-controlled, phase III trial
por: Kaku, K, et al.
Publicado: (2015)

CD40 agonist-induced IL-12p40 potentiates hepatotoxicity
por: Bonnans, Caroline, et al.
Publicado: (2020)

Fasiglifam (TAK-875) Alters Bile Acid Homeostasis in Rats and Dogs: A Potential Cause of Drug Induced Liver Injury
por: Wolenski, Francis S., et al.
Publicado: (2017)

Structural basis for GPR40 allosteric agonism and incretin stimulation
por: Ho, Joseph D., et al.
Publicado: (2018)

GPR40 partial agonists and AgoPAMs: Differentiating effects on glucose and hormonal secretions in the rodent
por: Pachanski, Michele J., et al.
Publicado: (2017)

Optical control of GPR40 signalling in pancreatic β-cells
por: Frank, James Allen, et al.
Publicado: (2017)

GPR40 modulates epileptic seizure and NMDA receptor function
por: Yang, Yong, et al.
Publicado: (2018)

Polyunsaturated fatty acid receptors, GPR40 and GPR120, are expressed in the hypothalamus and control energy homeostasis and inflammation
por: Dragano, Nathalia R. V., et al.
Publicado: (2017)

T40. GPR52 AGONISTS REPRESENT A NOVEL APPROACH TO TREAT UNMET MEDICAL NEED IN SCHIZOPHRENIA
por: Grottick, Andrew J, et al.
Publicado: (2018)

Evidence for NADPH oxidase activation by GPR40 in pancreatic β-cells
por: Nunes Marsiglio-Librais, Gabriela, et al.
Publicado: (2020)

GPR40 Agonism Modulates Inflammatory Reactions in Vascular Endothelial Cells
por: Kim, Joo Won, et al.
Publicado: (2022)

GPR40 agonist ameliorates liver X receptor-induced lipid accumulation in liver by activating AMPK pathway
por: Li, Meng, et al.
Publicado: (2016)

Activation of GPR40 as a Therapeutic Target for the Treatment of Type 2 Diabetes
por: Burant, Charles F.
Publicado: (2013)

Dysfunctional GPR40/FFAR1 signaling exacerbates pain behavior in mice
por: Nakamoto, Kazuo, et al.
Publicado: (2017)

A Potent Class of GPR40 Full Agonists Engages the EnteroInsular Axis to Promote Glucose Control in Rodents
por: Luo, Jian, et al.
Publicado: (2012)

Novel FFA1 (GPR40) agonists containing spirocyclic periphery: polar azine periphery as a driver of potency
por: Krasavin, Mikhail, et al.
Publicado: (2016)

The GPR40 Agonist GW9508 Enhances Neutrophil Function to Aid Bacterial Clearance During E. coli Infections
por: Souza, Patricia R., et al.
Publicado: (2020)

Molecular dynamics-guided discovery of an ago-allosteric modulator for GPR40/FFAR1
por: Lückmann, Michael, et al.
Publicado: (2019)

AMG 837: A Novel GPR40/FFA1 Agonist that Enhances Insulin Secretion and Lowers Glucose Levels in Rodents
por: Lin, Daniel C.-H., et al.
Publicado: (2011)

SCO-267, a GPR40 Full Agonist, Stimulates Islet and Gut Hormone Secretion and Improves Glycemic Control in Humans
por: Nishizaki, Harunobu, et al.
Publicado: (2021)

Formation of βTC3 and MIN6 Pseudoislets Changes the Expression Pattern of Gpr40, Gpr55, and Gpr119 Receptors and Improves Lysophosphatidylcholines-Potentiated Glucose-Stimulated Insulin Secretion
por: Drzazga, Anna, et al.
Publicado: (2020)

Gpr40 Is Expressed in Enteroendocrine Cells and Mediates Free Fatty Acid Stimulation of Incretin Secretion
por: Edfalk, Sara, et al.
Publicado: (2008)

The G-Protein-Coupled Long-Chain Fatty Acid Receptor GPR40 and Glucose Metabolism
por: Tomita, Tsutomu, et al.
Publicado: (2014)

Differential Gene Expression in GPR40-Overexpressing Pancreatic β-cells Treated with Linoleic Acid
por: Kim, In-Su, et al.
Publicado: (2015)

Activation of GPR40 induces hypothalamic neurogenesis through p38- and BDNF-dependent mechanisms
por: Engel, Daiane F., et al.
Publicado: (2020)

Pharmacophore-guided repurposing of fibrates and retinoids as GPR40 allosteric ligands with activity on insulin release
por: Cione, Erika, et al.
Publicado: (2021)

Thiazolidinediones (TZDs) enhance insulin secretory response via GPR40 and adenylate cyclase (AC)
por: Hwang, Mina, et al.
Publicado: (2021)

GPR40 partial agonist MK-2305 lower fasting glucose in the Goto Kakizaki rat via suppression of endogenous glucose production
por: Miller, Corin, et al.
Publicado: (2017)

A selective GPR40 (FFAR1) agonist LY2881835 provides immediate and durable glucose control in rodent models of type 2 diabetes
por: Chen, Yanyun, et al.
Publicado: (2016)

Activation of GPR40 attenuates chronic inflammation induced impact on pancreatic β-cells health and function
por: Verma, Mahesh Kumar, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_dja99ltj0j59o0asc7gpe0anlv